Understand the source comparison
LL-37 Peptide: Dosage Timing and Stability Comparison
Once daily (single injection) 4–6 hours 6–8 hours post-injection 12–18 hours (declining) 2–8°C for 28 days; freeze-thaw degrades potency Suboptimal. Peptide levels drop below effective threshold for >12 hours daily, reducing cumulative immune activation Twice
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Once daily (single injection)
- 4–6 hours
- 6–8 hours post-injection
- 12–18 hours (declining)
- 2–8°C for 28 days; freeze-thaw degrades potency
- Suboptimal. Peptide levels drop below effective threshold for >12 hours daily, reducing cumulative immune activation
- Twice daily (morning + evening)
- 4–6 hours per dose
- Sustained 12–16 hours with overlap
- 20–24 hours (sustained signalling)
- 2–8°C for 28 days; avoid temperature excursions >8°C
- Standard research protocol. Maintains therapeutic peptide concentration throughout dosing interval, aligns with immune cell recruitment kinetics
- Topical application (cream/gel)
- Variable (depends on vehicle)
- 4–8 hours at application site
- 8–12 hours localised
- Room temperature stable in anhydrous base; hydrogels degrade within 7 days
- Best for localised skin conditions. Systemic absorption minimal, peak tissue concentration at 2–4 hours post-application
- Twice-daily subcutaneous dosing at 2–5 mg per injection produces the most consistent tissue-level peptide concentrations across published wound healing studies. Single daily dosing saves material cost but sacrifices approximately 30–40% of potential immune modulation due to the extended trough period where peptide levels fall below the activation threshold for FPRL1 receptors.